28 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Novartis (Switzerland)CH3 papers
- Bayer (Germany)DE2 papers
- Boehringer Ingelheim (Germany)DE2 papers
- Bristol-Myers Squibb (Germany)DE2 papers
- Merck KGaA, Darmstadt (Germany)DE2 papers
- Pfizer (Germany)DE2 papers
- Roche (Switzerland)CH2 papers
- Universitätsmedizin GöttingenDE2 papers
- University of FreiburgDE2 papers
- Eli Lilly (Germany)DE1 paper
- Eli Lilly (United States)US1 paper
- Medical University of ViennaAT1 paper
3 papers
Optimal allocation strategies in platform trials
Marta Bofill Roig, Ekkehard Glimm, Tobias Mielke +1
Platform trials are randomized clinical trials that allow simultaneous comparison of multiple interventions, usually against a common control. Arms to test experimental interventio…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- estimation of adverse event risks
Regina Stegherr, Claudia Schmoor, Jan Beyersmann +12
The SAVVY project aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up tim…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Kaspar Rufibach, Regina Stegherr, Claudia Schmoor +12
Analyses of adverse events (AEs) are an important aspect of the evaluation of experimental therapies. The SAVVY (Survival analysis for AdVerse events with Varying follow-up times)…